Ucb S A (UCBJF) 80.0300 $UCBJF UCB Reveals Positive Data

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ucb S A (UCBJF) 80.0300 $UCBJF

UCB Reveals Positive Data on Vimpat Monotherapy Study
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:45PM CDT
UCB (UCBJF) announced encouraging top-line results from a phase III non-inferiority study on Vimpat monotherapy for newly diagnosed partial-onset seizures.
ADHD: 5.66 (+0.17), APRI: 1.65 (+0.03), ANAC: 115.06 (+2.13)

Catalyst Starts Congenital Myasthenic Syndromes Study
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 1:35PM CDT
Catalyst Pharmaceuticals (CPRX) initiated a pediatric study on Firdapse for congenital myasthenic syndromes in patients aged 2 years to 17 years.
BMRN: 102.69 (+1.97), CPRX: 3.18 (+0.10), APRI: 1.65 (+0.03)

Lannett (LCI) to Buy UCB's Specialty Generics Subsidiary
Zacks Equity Research - Zacks Investment Research - Thu Sep 03, 3:10PM CDT
Lannett Company (LCI) inked a deal with UCB to buy its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc.
LCI: 47.21 (+1.09), JNJ: 95.37 (+0.29), CORT: 3.74 (-0.05)

Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 3:50PM CDT
Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), NVS: 91.90 (-0.71)

Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 274.84 (-1.32), PGNX: 5.77 (+0.26), RDY: 65.69 (-0.23)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Immunomedics Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws
Business Wire - Tue Jul 28, 2:35PM CDT
Levi & Korsinsky is investigating the Board of Directors of Immunomedics Inc. ("Immunomedics" or the "Company" (NASDAQGM:IMMU) for possible violations of federal securities laws. The investigation concerns whether Immunomedics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 28, 2015, UCB SA, Immunomedics' collaboration partner, announced that their drug epratuzumab failed two Phase 3 studies. Upon the announcement of this news, the share price of Immunomedics stock plunged approximately $1.20, or 32%, in intraday trading from its closing price of $9.71 on July 27, 2015. To obtain additional information, go to:
IMMU: 2.17 (+0.12)

Week In Review: Livzon Leads $26 Million Funding Of Cynvenio
ChinaBio Today - at Seeking Alpha - Sun Jun 21, 4:57AM CDT
Deals and Financings Livzon Pharma (SZ: 000513 HK: 01513) of Zuhai, China, led a $25.5 million Series B funding of Cynvenio Biosystems, a Los Angeles area diagnostics company. Cynvenio is developing LiquidBiopsy, a technology that performs genomic...
JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), PFE: 33.24 (+0.15), WX: 44.15 (+0.04)

UCB to Expand Cimzia Label Based on Positive Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 1:50PM CDT
UCB S.A. (UCBJF) announced positive results from a phase III study on Cimzia for rheumatoid arthritis in DMARD-naive patients at high risk of disease progression.
VRX: 175.94 (+4.77), BIOD: 0.43 (+0.02)

Immunomedics' Drug Gets Fast Track Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 3:39PM CDT
Immunomedics, Inc. (IMMU) announced that the FDA has granted fast track designation to its lead antibody-drug conjugate program sacituzumab govitecan for the treatment of patients suffering from metastatic non-small cell lung cancer.
VRX: 175.94 (+4.77), IMMU: 2.17 (+0.12), PFE: 33.24 (+0.15)

Dr. Reddy's (RDY) Earnings and Revenues Rise in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 9:00AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 49 cents, up 8.9% from the year-ago quarter.
SUPN: 14.48 (+0.16), RDY: 65.69 (-0.23)

Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:45PM CDT
Immunomedics, Inc. (IMMU) provided an update on its lead ADC candidate, sacituzumab govitecan.
CRMD: 2.45 (+0.08), BIIB: 269.16 (-10.72), IMMU: 2.17 (+0.12)

UCB to Sell Indian Established Brands Portfolio to Dr. Reddy's - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 1:40PM CDT
UCB S.A. (UCBJF) will sell its established brands portfolio in India, to Dr. Reddy's Laboratories Ltd. to focus on core business.
CYTK: 7.00 (+0.02), LCI: 47.21 (+1.09), RDY: 65.69 (-0.23)

Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 269.16 (-10.72), ACT: 298.98 (-2.94), VRX: 175.94 (+4.77), PCYC: 261.25 (+1.70), OSIR: 16.97 (+0.31), ACOR: 29.89 (-0.22), HSP: 89.95 (-0.01), AGN: 274.84 (-1.32), MDVN: 41.26 (+2.03), ESRX: 82.72 (+0.01), SHPG: 200.90 (-1.85), ABBV: 55.64 (-0.40), SNY: 48.75 (+0.03), ARNA: 2.19 (+0.14), REGN: 503.92 (+12.71), ABT: 41.89 (+0.73), ENDP: 64.27 (+0.85), AKRX: 29.90 (+0.39), PFE: 33.24 (+0.15), INCY: 105.00 (+1.56), SLXP: 172.96 (+0.15), AMGN: 149.59 (-0.31), MYL: 42.55 (-0.12), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), ALKS: 60.82 (+0.92), MNKD: 3.05 (+0.04), OREX: 2.53 (+0.15), NVO: 54.61 (-0.12), ISIS: 43.24 (+0.86), GERN: 3.07 (+0.10), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)

Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 269.16 (-10.72), ACT: 298.98 (-2.94), VRX: 175.94 (+4.77), PCYC: 261.25 (+1.70), OSIR: 16.97 (+0.31), ACOR: 29.89 (-0.22), HSP: 89.95 (-0.01), AGN: 274.84 (-1.32), MDVN: 41.26 (+2.03), ESRX: 82.72 (+0.01), SHPG: 200.90 (-1.85), ABBV: 55.64 (-0.40), SNY: 48.75 (+0.03), ARNA: 2.19 (+0.14), REGN: 503.92 (+12.71), ABT: 41.89 (+0.73), ENDP: 64.27 (+0.85), AKRX: 29.90 (+0.39), PFE: 33.24 (+0.15), INCY: 105.00 (+1.56), SLXP: 172.96 (+0.15), AMGN: 149.59 (-0.31), MYL: 42.55 (-0.12), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), ALKS: 60.82 (+0.92), MNKD: 3.05 (+0.04), OREX: 2.53 (+0.15), NVO: 54.61 (-0.12), ISIS: 43.24 (+0.86), GERN: 3.07 (+0.10), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)

UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 47.21 (+1.09), SCMP: 18.19 (-1.21), BIOD: 0.43 (+0.02)

Week In Review: WuXi NextCode Leads $15 Million Financing In Claritas Genomics
ChinaBio Today - at Seeking Alpha - Sun Feb 08, 3:46AM CST
Deals and Financings WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech (NYSE: WX ), led a $15 million Series B financing in Claritas Genomics (see story ). Claritas is a Boston-based lab that...
MRK: 50.95 (-0.07), WX: 44.15 (+0.04)

UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 6:00PM CST
UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in the U.S. and the EU.
BCRX: 8.80 (-0.95), AMGN: 149.59 (-0.31), BIOD: 0.43 (+0.02)

Immunomedics Reports Data on Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:05PM CST
Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
IMMU: 2.17 (+0.12), PFE: 33.24 (+0.15), BIOD: 0.43 (+0.02)

UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 1:10PM CST
UCB S.A. (UCBJF) and Neuropore Therapies Inc. entered into a collaboration agreement for the development and commercialization of Parkinson's disease related therapies.
LCI: 47.21 (+1.09), ENDP: 64.27 (+0.85), BIOD: 0.43 (+0.02)

UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:05PM CST
UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe chronic plaque psoriasis.
SHPG: 200.90 (-1.85), AMGN: 149.59 (-0.31), NVS: 91.90 (-0.71)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 19

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 84

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 25

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 74

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 130

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 133

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 21

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Qfin Holdings Faces Securities Fraud Lawsuit Scrutiny

Updated Category News Views 23

Qfin Holdings Stumbles Under Legal Microscope Picture this—you're riding the stock market wave and then, out of nowhere, your investment gets hit by a sudden drop, leaving you scrambling for answers. That's the scenario investors in Qfin Holdings, Inc. (NASDAQ: QFIN) find themselves in after the company’s stock plunged by nearly 19%. Now, they're not just left...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 44

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights into Rathbones Group Plc's Position Disclosure

Updated Category News Views 171

Understanding Disclosure Requirements in Financial Markets In the world of finance and investments, transparency is paramount. Investors and market participants must be aware of regulations surrounding disclosure, especially when significant interest in relevant securities occurs. Here, we delve into key details surrounding a recent public disclosure by Rathbones Group...

Continue Reading
Atkore Inc. Announces Quarterly Cash Dividend for Shareholders

Updated Category News Views 139

Atkore Inc. Announces Cash Dividend for Shareholders Atkore Inc. (NYSE: ATKR), a prominent manufacturer known for its extensive electrical products, has informed its investors about the declaration of a quarterly cash dividend. This announcement signifies the company's ongoing commitment to providing value to its shareholders. The dividend is set at $0.32 per share of...

Continue Reading
Innovating Home Textiles: How CiCLO® is Changing Luxury Fabrics

Updated Category News Views 248

Innovative Technologies in Home Textiles An innovative fiber design blending renewable and biodegradable materials is advancing comfort, longevity, and responsible performance in premium home and hospitality textiles. At Heimtextil 2026, Intrinsic Advanced Materials will showcase a new generation of luxury textiles that embody sustainable practices, collaborating with...

Continue Reading
Vegan Food Industry Set for Huge Growth: USD 55.88 Billion by 2034

Updated Category News Views 271

Overview of the Vegan Food Market Growth The global vegan food market is anticipated to witness significant growth, increasing from USD 20.22 billion to an impressive USD 55.88 billion by 2034. This remarkable shift, with a compound annual growth rate (CAGR) of 10.7% from 2025 to 2034, reflects the rising consumer demand for plant-based options. Consumer Trends Driving...

Continue Reading
BAOS Stock Hits New Heights with Investor Enthusiasm

Updated Category News Views 190

BAOS Stock Surges to 52-Week High In a remarkable display of market confidence, Baosheng Media Group Holdings Limited (BAOS) has achieved a significant milestone by reaching a 52-week high of $7.33 per share. This surge demonstrates the strong backing from investors and the company's solid financial standing. Company Valuation and Financial Health The micro-cap company,...

Continue Reading